Find A Clinical Trial

Disease Type: Breast

Trial ID 22018
Sponsor ID Genentech

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Principal Investigator
Anne Favret, MD
3 Locations
Trial ID 21380
Sponsor ID post-MONARCH

postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Principal Investigator
Anne Favret, MD
3 Locations
Trial ID 21234
Sponsor ID ARTEST

(V3002401) ARTEST – A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining greater than or equal to 40% Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK…

Principal Investigator
Anne Favret, MD
3 Locations
Trial ID TWT-203
Sponsor ID Treadwell Therapeutics

PHASE 1b/2 DOSE-CONFIRMING, MULTIPART, MULTICENTER STUDY OF CFI-402257 AS A SINGLE AGENT IN ADVANCED SOLID TUMORS AND IN COMBINATION WITH FULVESTRANT IN PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER AFTER DISEASE PROGRESSION ON PRIOR CDK4/6 AND ENDOCRINE THERAPY

1 Location
Trial ID LAE205INT3101
Sponsor ID Laekna

A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies

Principal Investigator
Shruti Tiwari, MD
3 Locations
Trial ID 20363
Sponsor ID SERENA-4

SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Principal Investigator
Anne Favret, MD
3 Locations
Trial ID 19226
Sponsor ID F. Hoffman/LaRoche

A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Principal Investigator
Anne Favret, MD
3 Locations
Trial ID NUV-422-03
Sponsor ID Nuvation Bio

Randomized, Non-Comparative Phase 1/2 Study of NUV-422 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive Epidermal Growth Factor Receptor2-Negative (HR+ HER2-) Advanced Breast Cancer

1 Location
Trial ID RLY-2608-101
Sponsor ID Relay Therapeutics

A First-in-Human Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer